The Biotechnology segment includes sales made through R&D Systems' Biotechnology Division, R&D Systems Europe, Tocris, R&D Systems China, BiosPacific and Boston Biochem. Biotechnology segment net sales were $78.2 million for the quarter ended March 31, 2012, an increase of 9.9% from $71.1 million for the quarter ended March 31, 2011. Biotechnology net sales were $220 million for the nine-month period ended March 31, 2012, an increase of 11.7% from $197 million for the nine-month period ended March 31, 2011. Biotechnology sales growth was 1.5% and 2.0% for the quarter and nine month periods ended March 31, 2012, respectively, if sales from the acquisitions and foreign currency effect are excluded.
Organic sales growth for the Biotechnology segment from the same prior-year periods were:Period Ended March 31, 2012Quarter
Nine MonthsU.S. industrial, pharmaceutical and biotechnology
6.5%Hematology net sales for the quarter and nine-month period ended March 31, 2012 were $5.4 million and $15.6 million, increases of 5.6% and 6.2%, respectively, from the comparable prior-year periods.
The gross margin percentage declined to 75.8% in the quarter ended March 31, 2012 from 79.1% in the comparable prior-year quarter and to 75.0% in the nine-month period ended March 31, 2012 from 78.0% in the comparable prior-year period, due to costs recognized upon the sale of inventory that was written-up to fair value as part of the acquisitions and the amortization of intangible assets. Gross margins were 79.0% and 79.2% for the quarters ended March 31, 2012 and 2011, respectively, and 78.5% and 78.2% for the nine-month periods ended March 31, 2012 and 2011, respectively, if such cos
|SOURCE Techne Corporation|
Copyright©2010 PR Newswire.
All rights reserved